Vuorela, A.
Freitag, T. L. http://orcid.org/0000-0001-5971-2991
Leskinen, K.
Pessa, H.
Härkönen, T.
Stracenski, I.
Kirjavainen, T.
Olsen, P.
Saarenpää-Heikkilä, O.
Ilonen, J.
Knip, M. http://orcid.org/0000-0003-0474-0033
Vaheri, A.
Partinen, M.
Saavalainen, P.
Meri, S.
Vaarala, O.
Article History
Received: 7 August 2019
Accepted: 18 March 2021
First Online: 16 April 2021
Competing interests
: O.V. is an employee of Orion Pharma since June 2019 and was an employee of AstraZeneca/Medimmune from August 2014 to June 2019. This research was started before she joined AstraZeneca, and neither Orion Pharma nor AstraZeneca have a role in this study. M.P. is a member of the Medical Advisory Board of Bioprojet and UCB Pharma. He has been involved in clinical trials on narcolepsy with Bioprojet, Jazz Pharmaceuticals, and UCB Pharma. These roles are not related to this research project. I.S. is an employee of Janssen Pharmaceuticals. This research was started before she joined Janssen, and Janssen has no role in this study. P.S is the CEO and board chair of SCellex, which has no role in this study. K.L. and H.P. are employees of SCellex. The other authors have no competing interests to declare.